Prescribing information

 

Cosentyx® (secukinumab) in rheumatology

Cosentyx is indicated alone or in combination with methotrexate, for the treatment of active PsA in adult patients when the response to previous DMARDs has been inadequate, for the treatment of active AS in adults who have responded inadequately to conventional therapy, and for the treatment of active nr-axSpA, with objective signs of inflammation, as indicated by elevated C-reactive protein and/or MRI evidence, in adults who have responded inadequately to NSAIDs

Evolving rheumatology services to support PsA patients in a new world:
BSR 2021, Wednesday 28 April, 12:30–13:15

Please join us at the virtual BSR 2021 conference where our multidisciplinary panel of experts Dr Antoni Chan, Dr Kirsten MacKay, Julie Begum, and Anusha Patel will lead an interactive discussion on:

  • The significance of early diagnosis, recognition, and treatment of the multiple manifestations of PsA
  • Current approaches to service delivery to support patients with PsA, taking into account the contribution of supplementary services, such as nurse-led clinics     
  • The impact of COVID-19 on rheumatology services and patients, and potential solutions as we emerge from the pandemic 

 

To see this event, register for the BSR annual conference at:
https://www.rheumatology.org.uk/events-learning/conferences/annual-conference


Click to hear more about our BSR symposium from the Chairperson, Dr Antoni Chan

 

 

Join us at the virtual BSR annual conference at 12:30–13:15 on Wednesday 28 April 2021

Time Title Presenter
12:30–12:35 Welcome and introduction Dr Antoni Chan
Consultant Rheumatologist, Royal Berkshire NHS Foundation Trust
12:35–12:55 Shared perspectives: Key insights into the patient journey Dr Kirsten MacKay
Consultant Rheumatologist, Torbay and South Devon NHS Foundation Trust
 
Dr Antoni Chan
Consultant Rheumatologist, Royal Berkshire NHS Foundation Trust
12:55–13:15 Building momentum: How do we reboot rheumatology practices post-pandemic? Julie Begum
Clinical Nurse Specialist, Luton and Dunstable NHS Trust
 
Anusha Patel
Regional Homecare Lead East Midlands, Kettering General Hospital NHS Foundation Trust
 
Dr Kirsten MacKay
Consultant Rheumatologist, Torbay and South Devon NHS Foundation Trust
 
Moderator: Dr Antoni Chan
Consultant Rheumatologist, Royal Berkshire NHS Foundation Trust

Take the next step

We’re here to support you with dedicated representatives up and down the country. Let us connect you with your local representative to discuss how you can get the most out of Cosentyx.

Or find out more using the links below...

Arrow with the text: Hear from the experts. Click image to find out more

Arrow with the text: Why Cosentyx in PsA? Click image to find out more

Arrow with the text: Why Cosentyx in axSpA? Click image to find out more

Arrow with the text: Discover our patient support programme. Click image to find out more

Arrow with the text: Can targeting IL-17A make the difference? Click image to find out more

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; BSR, British Society for Rheumatology; COVID-19, coronavirus disease 2019; DMARD, disease-modifying antirheumatic drug; IL, interleukin; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, psoriasis.

UK | April 2021 | 114403
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]